Aldeyra Therapeutics Management
Management criteria checks 2/4
Aldeyra Therapeutics' CEO is Todd Brady, appointed in Jan 2012, has a tenure of 12.25 years. total yearly compensation is $3.68M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 1.94% of the company’s shares, worth €4.24M. The average tenure of the management team and the board of directors is 2.9 years and 10.7 years respectively.
Key information
Todd Brady
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 15.8% |
| CEO tenure | 12.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 2.9yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$581k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$61m |
| Dec 31 2022 | US$3m | US$559k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$3m | US$547k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$53m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$2m | US$544k | -US$38m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$4m | US$523k | -US$61m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$50m |
| Mar 31 2019 | n/a | n/a | -US$46m |
| Dec 31 2018 | US$3m | US$506k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$2m | US$473k | -US$22m |
Compensation vs Market: Todd's total compensation ($USD3.68M) is above average for companies of similar size in the German market ($USD691.02K).
Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.
CEO
Todd Brady (51 yo)
12.3yrs
Tenure
US$3,684,651
Compensation
Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 12.3yrs | US$3.68m | 1.94% $ 4.2m | |
| Senior VP of Finance | 1.9yrs | US$974.07k | 0.060% $ 130.5k | |
| Chief Development Officer | 3.3yrs | US$1.59m | 0.14% $ 299.2k | |
| Vice President of Commercial Strategy & Operations | 2.5yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data |
2.9yrs
Average Tenure
51yo
Average Age
Experienced Management: 137's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 19.3yrs | US$3.68m | 1.94% $ 4.2m | |
| Independent Chair of the Board | 7.6yrs | US$221.98k | 0.21% $ 458.2k | |
| Independent Director | 13.8yrs | US$190.40k | 0.048% $ 103.5k | |
| Independent Director | 14.9yrs | US$194.07k | 0.025% $ 54.3k | |
| Independent Director | 10.5yrs | US$195.66k | 0.040% $ 87.9k | |
| Independent Director | 10.8yrs | US$174.22k | 0.027% $ 58.1k | |
| Member of Retina Segment Scientific Advisory Board | no data | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$174.22k | 0% $ 0 | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data |
10.7yrs
Average Tenure
64yo
Average Age
Experienced Board: 137's board of directors are seasoned and experienced ( 10.7 years average tenure).